trending Market Intelligence /marketintelligence/en/news-insights/trending/iBghxq5eS_q802y7NOYPyw2 content esgSubNav
In This List

Master Pharm Q1 profit climbs 56.3% YOY

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Blog

Lithium and Cobalt - Softer demand weighs on prices

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Podcast

Next in Tech | Episode 65: The operations side of AI/ML


Master Pharm Q1 profit climbs 56.3% YOY

Master Pharm SA said its first-quarter normalized net income came to 1.3 million zlotys, a rise of 56.3% from 800,630 zlotys in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin fell to 10.9% from 11.3% in the year-earlier period.

Total revenue rose 61.0% on an annual basis to 11.5 million zlotys from 7.1 million zlotys, and total operating expenses rose 61.3% on an annual basis to 9.4 million zlotys from 5.9 million zlotys.

Reported net income increased 28.8% year over year to 1.3 million zlotys, or 7 groszy per share, from 1.0 million zlotys.

As of May 16, US$1 was equivalent to 3.85 zlotys.